Can-Fite BioPharma Ltd. (CANF)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jul. 24, 2025 | CORRESP | Neutral/Informational | Moderate | Can-Fite BioPharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement No. 333-288890 on Form F-1. The company seeks to… | Read Filing EDGAR |
| Jul. 24, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from H.C. Wainwright & Co., LLC to the U.S. Securities and Exchange Commission indicates their concurrence with Can-Fite BioPharma Ltd.'s request to accelerate … | Read Filing EDGAR |
| Jul. 22, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Can-Fite BioPharma Ltd.'s Form 20-F for the fiscal year ended December 31, 2024. The correspondence emphasizes that the responsibility for the … | Read Filing EDGAR |
| Jul. 17, 2025 | CORRESP | Neutral/Informational | Low | Can-Fite BioPharma Ltd. submitted a response to the SEC regarding comments on their Form 20-F for the fiscal year ended December 31, 2024. The SEC requested more detailed disclosu… | Read Filing EDGAR |
| Jul. 15, 2025 | UPLOAD | Neutral/Informational | Low | The SEC correspondence dated July 15, 2025, informs Motti Farbstein, CEO of Can-Fite BioPharma Ltd., that the SEC does not intend to review their Draft Registration Statement of F… | Read Filing EDGAR |
| Jun. 17, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Can-Fite BioPharma Ltd.'s Form 20-F for the fiscal year ended December 31, 2024, focusing on the financial statements and related disclos… | Read Filing EDGAR |